Neurorevive

NeuroReVive operates at the intersection of neurorehabilitation, assistive wearables, medical devices, and biomedical robotics. Its positioning centers on a non-invasive, fully wireless orthosis that combines real-time biosignal decoding with ergonomic hardware to support hand movement after stroke or traumatic nerve injury. That focus distinguishes it from rehabilitation platforms centered primarily on passive therapy, clinic-based robotics, or general-purpose wearable monitoring. The company’s stated use of residual neural and muscle signals also gives it a more specific control proposition than products that rely only on preset mechanical assistance. The company is materially smaller and earlier-stage than established medical-device and neurotechnology providers, with one pre-seed round and an employee range of one to ten people. Its market position is therefore best characterized as an early technology entrant pursuing a focused hand-recovery application, with differentiation driven by wireless operation, AI-enabled signal interpretation, and everyday-use ergonomics.

NeuroReVive was founded on Jun 12, 2023 and announced a single pre-seed financing of $163,506 on Jul 18, 2024. That sequence indicates a young company moving from formation into funded prototype development rather than a business with a demonstrated multi-round scaling history. The Wireless Exoskeleton Glove is the main identifiable product, and its design combines biosignal sensing, AI interpretation, and mechanical assistance in a wearable form factor. The reported demonstration of a person with chronic paralysis grasping and drinking from a glass in under 30 seconds represents an important functional inflection point because it connects the underlying technology to an everyday activity. Website materials also describe a broader software and cloud application ecosystem, suggesting a potential path beyond hardware alone, although no deployment, revenue, regulatory, or clinical-trial milestones are documented. The company’s employee range remains one to ten, and there is no reported hiring activity or layoff event.